Skip to main content

Jose Ramon Conejo-Garcia

Professor in Integrative Immunobiology
Integrative Immunobiology
2128 Msrbiii, 3 Genome Ct, Durham, NC 27710

Selected Publications


Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy

Journal Article Cells · June 28, 2024 Understanding tumor–host immune interactions and the mechanisms of lung cancer response to immunotherapy is crucial. Current preclinical models used to study this often fall short of capturing the complexities of human lung cancer and lead to incon ... Full text Cite

Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors.

Journal Article Cancer Epidemiol Biomarkers Prev · June 3, 2024 BACKGROUND: Cigarette smoke exposure has been linked to systemic immune dysfunction, including for B-cell and immunoglobulin (Ig) production, and poor outcomes in patients with ovarian cancer. No study has evaluated the impact of smoke exposure across the ... Full text Link to item Cite

Supplemental Table 9 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 9: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells among Type II tumors, NHS and NHSII</p> ... Full text Cite

Data from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <div>AbstractBackground:<p>Cigarette smoke exposure has been linked to systemic immune dysfunction, including for B-cell and immunoglobulin (Ig) production, and poor outcomes in patients with ovarian cancer. No study has evaluated the i ... Full text Cite

Supplemental Table 7 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 7: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells, NHS and NHSII</p> ... Full text Cite

Supplemental Table 6 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 6: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by adult smoking status among cases only within two years before diagnosis, NHS and ... Full text Cite

Supplemental Figure 1 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Figure 1: Flow chart for the selection of ovarian cancer cases in the Nurses’ Health Study (NHS) and NHSII, limited to ovarian cancer diagnosis, available tissue, available data on parental smoke exposure, and successful multi ... Full text Cite

Supplemental Table 8 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 8: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins, NHS and NHSII</p> ... Full text Cite

Supplemental Table 3 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 3: Characteristics of women with ovarian cancer in NHS and NHSII, overall and who had tumor tissue on the TMAs and information about lifetime cigarette smoke exposure</p> ... Full text Cite

Supplemental Table 4 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 4: Percent positive immune cells or Ig positive cells in the tumor among all cells in the tumor by ovarian tumor subtype in NHS and NHSII</p> ... Full text Cite

Supplemental Table 6 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 6: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by adult smoking status among cases only within two years before diagnosis, NHS and ... Full text Cite

Supplemental Table 9 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 9: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells among Type II tumors, NHS and NHSII</p> ... Full text Cite

Supplemental Table 2 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 2: Age-standardized baseline characteristics by parental smoking during childhood or adolescence, NHS (1982) and NHSII (1999)</p> ... Full text Cite

Supplemental Table 10 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 10: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins among Type II tumors, NHS and NHSII</p> ... Full text Cite

Supplemental Table 8 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 8: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins, NHS and NHSII</p> ... Full text Cite

Supplemental Table 5 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 5: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by smoking status among cases in NHS only</p> ... Full text Cite

Supplemental Table 4 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 4: Percent positive immune cells or Ig positive cells in the tumor among all cells in the tumor by ovarian tumor subtype in NHS and NHSII</p> ... Full text Cite

Supplemental Figure 1 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Figure 1: Flow chart for the selection of ovarian cancer cases in the Nurses’ Health Study (NHS) and NHSII, limited to ovarian cancer diagnosis, available tissue, available data on parental smoke exposure, and successful multi ... Full text Cite

Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy

Journal Article Cells · June 28, 2024 Understanding tumor–host immune interactions and the mechanisms of lung cancer response to immunotherapy is crucial. Current preclinical models used to study this often fall short of capturing the complexities of human lung cancer and lead to incon ... Full text Cite

Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors.

Journal Article Cancer Epidemiol Biomarkers Prev · June 3, 2024 BACKGROUND: Cigarette smoke exposure has been linked to systemic immune dysfunction, including for B-cell and immunoglobulin (Ig) production, and poor outcomes in patients with ovarian cancer. No study has evaluated the impact of smoke exposure across the ... Full text Link to item Cite

Supplemental Table 9 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 9: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells among Type II tumors, NHS and NHSII</p> ... Full text Cite

Data from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <div>AbstractBackground:<p>Cigarette smoke exposure has been linked to systemic immune dysfunction, including for B-cell and immunoglobulin (Ig) production, and poor outcomes in patients with ovarian cancer. No study has evaluated the i ... Full text Cite

Supplemental Table 7 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 7: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells, NHS and NHSII</p> ... Full text Cite

Supplemental Table 6 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 6: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by adult smoking status among cases only within two years before diagnosis, NHS and ... Full text Cite

Supplemental Figure 1 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Figure 1: Flow chart for the selection of ovarian cancer cases in the Nurses’ Health Study (NHS) and NHSII, limited to ovarian cancer diagnosis, available tissue, available data on parental smoke exposure, and successful multi ... Full text Cite

Supplemental Table 8 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 8: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins, NHS and NHSII</p> ... Full text Cite

Supplemental Table 3 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 3: Characteristics of women with ovarian cancer in NHS and NHSII, overall and who had tumor tissue on the TMAs and information about lifetime cigarette smoke exposure</p> ... Full text Cite

Supplemental Table 4 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 4: Percent positive immune cells or Ig positive cells in the tumor among all cells in the tumor by ovarian tumor subtype in NHS and NHSII</p> ... Full text Cite

Supplemental Table 6 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 6: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by adult smoking status among cases only within two years before diagnosis, NHS and ... Full text Cite

Supplemental Table 9 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 9: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells among Type II tumors, NHS and NHSII</p> ... Full text Cite

Supplemental Table 2 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 2: Age-standardized baseline characteristics by parental smoking during childhood or adolescence, NHS (1982) and NHSII (1999)</p> ... Full text Cite

Supplemental Table 10 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 10: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins among Type II tumors, NHS and NHSII</p> ... Full text Cite

Supplemental Table 8 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 8: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins, NHS and NHSII</p> ... Full text Cite

Supplemental Table 5 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 5: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by smoking status among cases in NHS only</p> ... Full text Cite

Supplemental Table 4 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 4: Percent positive immune cells or Ig positive cells in the tumor among all cells in the tumor by ovarian tumor subtype in NHS and NHSII</p> ... Full text Cite

Supplemental Figure 1 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Figure 1: Flow chart for the selection of ovarian cancer cases in the Nurses’ Health Study (NHS) and NHSII, limited to ovarian cancer diagnosis, available tissue, available data on parental smoke exposure, and successful multi ... Full text Cite

Supplemental Table 2 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 2: Age-standardized baseline characteristics by parental smoking during childhood or adolescence, NHS (1982) and NHSII (1999)</p> ... Full text Cite

Supplemental Table 10 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 10: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of immunoglobulins among Type II tumors, NHS and NHSII</p> ... Full text Cite

Supplemental Table 7 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 7: Hazard ratios and 95% confidence intervals between smoking and ovarian cancer risk by tumor immune infiltration of B cells, NHS and NHSII</p> ... Full text Cite

Supplemental Table 3 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 3: Characteristics of women with ovarian cancer in NHS and NHSII, overall and who had tumor tissue on the TMAs and information about lifetime cigarette smoke exposure</p> ... Full text Cite

Supplemental Table 5 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <p>Supplemental Table 5: Odds ratios and 95% confidence intervals for positivity of tumor immune infiltration of various types of B cells and immunoglobulins by smoking status among cases in NHS only</p> ... Full text Cite

Data from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors

Other · June 3, 2024 <div>AbstractBackground:<p>Cigarette smoke exposure has been linked to systemic immune dysfunction, including for B-cell and immunoglobulin (Ig) production, and poor outcomes in patients with ovarian cancer. No study has evaluated the i ... Full text Cite

Data from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <div>AbstractBackground:<p>Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Data from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <div>AbstractBackground:<p>Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Data from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <div>AbstractBackground:<p>Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · May 17, 2024 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Harnessing γδ T Cells against Human Gynecologic Cancers.

Journal Article Life (Basel) · February 29, 2024 Immuno-oncology has traditionally focused on conventional MHC-restricted αβ T cells. Yet, unconventional γδ T cells, which kill tumor cells in an MHC-unrestricted manner, display characteristics of effector activity and stemness without exhaustion and are ... Full text Link to item Cite

Immune landscape in molecular subtypes of human papillomavirus-negative head and neck cancer.

Journal Article Mol Carcinog · January 2024 Head and neck squamous cell carcinomas (HNSCC) remain a poorly understood disease clinically and immunologically. HPV is a known risk factor of HNSCC associated with better outcome, whereas HPV-negative HNSCC are more heterogeneous in outcome. Gene express ... Full text Link to item Cite

Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function.

Journal Article Res Sq · December 14, 2023 Mounting effective immunity against pathogens and tumors relies on the successful metabolic programming of T cells by extracellular fatty acids1-3. During this process, fatty-acid-binding protein 5 (FABP5) imports lipids that fuel mitochondrial respiration ... Full text Link to item Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Data from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · November 20, 2023 <div>AbstractBackground:<p>Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ... Full text Cite

Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.

Journal Article Immunity · November 14, 2023 Dimeric IgA (dIgA) can move through cells via the IgA/IgM polymeric immunoglobulin receptor (PIGR), which is expressed mainly on mucosal epithelia. Here, we studied the ability of dIgA to target commonly mutated cytoplasmic oncodrivers. Mutation-specific d ... Full text Link to item Cite

The relationship of lifetime history of depression on the ovarian tumor immune microenvironment.

Journal Article Brain, behavior, and immunity · November 2023 BackgroundDepression is associated with a higher ovarian cancer risk. Prior work suggests that depression can lead to systemic immune suppression, which could potentially alter the anti-tumor immune response.MethodsWe evaluated the associ ... Full text Cite

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors.

Journal Article Cancers (Basel) · October 10, 2023 BACKGROUND: We aimed to determine the prognostic value of an immunoscore reflecting CD3+ and CD8+ T cell density estimated from real-world transcriptomic data of a patient cohort with advanced malignancies treated with immune checkpoint inhibitors (ICIs) i ... Full text Link to item Cite

A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.

Journal Article Clin Cancer Res · October 2, 2023 PURPOSE: Immune checkpoint blockade holds promise for treating bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). In this phase II study, we investigated the safety and efficacy of durvalumab, a human IgG1 monoclonal an ... Full text Link to item Cite

Data from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

Other · October 2, 2023 <div>AbstractPurpose:<p>Immune checkpoint blockade holds promise for treating bacillus Calmette-Guerin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC). In this phase II study, we investigated the safety and efficacy of dur ... Full text Cite

Data from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

Other · October 2, 2023 <div>AbstractPurpose:<p>Immune checkpoint blockade holds promise for treating bacillus Calmette-Guerin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC). In this phase II study, we investigated the safety and efficacy of dur ... Full text Cite

Sézary syndrome originates from heavily mutated hematopoietic progenitors.

Journal Article Blood Adv · September 26, 2023 The pathogenesis of cutaneous T-cell lymphoma (CTCL) remains unclear. Using single-cell RNA or T-cell receptor (TCR) sequencing of 32 619 CD3+CD4+ and CD26+/CD7+ and 29 932 CD3+CD4+ and CD26-/CD7- lymphocytes from the peripheral blood of 7 patients with CT ... Full text Link to item Cite

Associations between prediagnostic aspirin use and ovarian tumor gene expression.

Journal Article Cancer Med · September 2023 BACKGROUND: Aspirin use has been associated with reduced ovarian cancer risk, yet the underlying biological mechanisms are not fully understood. To gain mechanistic insights, we assessed the association between prediagnosis low and regular-dose aspirin use ... Full text Link to item Cite

Virtual alignment of pathology image series for multi-gigapixel whole slide images.

Journal Article Nat Commun · July 26, 2023 Interest in spatial omics is on the rise, but generation of highly multiplexed images remains challenging, due to cost, expertise, methodical constraints, and access to technology. An alternative approach is to register collections of whole slide images (W ... Full text Link to item Cite

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.

Journal Article Int J Radiat Oncol Biol Phys · July 15, 2023 PURPOSE: We hypothesized that concurrent ipilimumab with chemoradiationtherapy (chemoRT) followed by maintenance nivolumab would be safe for patients with unresectable stage III non-small cell lung cancer (NSCLC). We aimed to assess the safety (phase 1) an ... Full text Link to item Cite

Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.

Journal Article Cancer Immunol Immunother · June 2023 Radiation therapy (RT) can prime and boost systemic anti-tumor effects via STING activation, resulting in enhanced tumor antigen presentation and antigen recognition by T cells. It is increasingly recognized that optimal anti-tumor immune responses benefit ... Full text Link to item Cite

Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies.

Journal Article Cancer Epidemiol Biomarkers Prev · June 1, 2023 BACKGROUND: Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ovarian tumor immune microenvironm ... Full text Link to item Cite

Actionable spontaneous antibody responses antagonize malignant progression in ovarian carcinoma.

Journal Article Gynecol Oncol · June 2023 OBJECTIVE: To demonstrate that shared antibody responses in endometriosis and endometriosis-associated ovarian cancer spontaneously antagonize malignant progression and can be leveraged to develop future immunotherapies. METHODS: B cells from cyopreserved ... Full text Link to item Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Data from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <div>AbstractBackground:<p>Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · June 1, 2023 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplementary Figure S6 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>TIMEx scores for the Immune gene signature among the 15 patients classified into the Hypoxia, Mixture and Immune subgroups.</p> ... Full text Cite

Supplementary Figure S1 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>(A, B) Heatmap of molecular subgroups in two different HNSCC datasets (A) TCGA and (B) CPTAC. RNA expression data was z-normalized, each row represents a single gene in the hypoxia-immune signature gene list, each column represents a patie ... Full text Cite

FIGURE 1 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Molecular classification and validation of hypoxia-immune signature in HNSCC. <b>A,</b> Heatmap of molecular subgroups in the Moffitt (<i>n</i> = 228) HNSCC cohort. RNA expression data were z-normalized, each row re ... Full text Cite

FIGURE 4 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Hypoxia subgroup has an enrichment of EGFR pathway. Pearson correlation coefficient for the TIMEx scores for the EGFR pathway and the Hypoxia gene signature among the TCGA (<b>A</b>), CPTAC (<b>B</b>), and Moffitt ( ... Full text Cite

FIGURE 3 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>GSEA of hallmark pathways in TCGA and Moffitt cohorts. TCGA (<b>A–C</b>) and Moffitt head and neck squamous cell carcinoma (<b>D–F</b>) cohorts. The gene expressions were compared for pathways enriched in: (<b&gt ... Full text Cite

Supplementary Figure S5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Protein network analysis of core-enriched genes within the hypoxia signature and TGF-β signaling from GSEA analysis. Clustering was performed using the STRING database. Three main clusters are depicted: hypoxia (blue color), TGF-β (green c ... Full text Cite

FIGURE 5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Cetuximab treatment benefits Hypoxia subgroup. <b>A,</b> Heatmap of gene expression data from pre- and post-cetuximab (CTX) treated patient samples. RNA expression data (GSE109756) was z-normalized, each row represents a single ... Full text Cite

Supplementary Figure S5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Protein network analysis of core-enriched genes within the hypoxia signature and TGF-β signaling from GSEA analysis. Clustering was performed using the STRING database. Three main clusters are depicted: hypoxia (blue color), TGF-β (green c ... Full text Cite

FIGURE 4 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Hypoxia subgroup has an enrichment of EGFR pathway. Pearson correlation coefficient for the TIMEx scores for the EGFR pathway and the Hypoxia gene signature among the TCGA (<b>A</b>), CPTAC (<b>B</b>), and Moffitt ( ... Full text Cite

Supplementary Figure S4 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>(A-C) Clinical Proteomic Tumor Analysis Consortium head and neck squamous cell carcinoma cohort. The gene expressions were compared for pathways enriched in: (A) Immune vs Hypoxia. Red: enriched in Immune, Blue: enriched in Hypoxia. (B) Im ... Full text Cite

Supplementary Figure S2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>(A, B) Representative mIHC images showing staining of nuclei (blue), tumor cell (orange - PCK) and selected immune checkpoint markers in each molecular subgroup. (A) Images show four lymphoid markers - CD3+ T-cells (Green), CD8+ cytotoxic ... Full text Cite

Supplementary Figure S3 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Heatmap of molecular subgroups in MCC18754 (n=48). RNA expression data was z-normalized, each row represents a single gene in the Hypoxia-Immune signature gene list, each column represents a patient sample. Samples were reordered according ... Full text Cite

Supplementary Figure S4 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>(A-C) Clinical Proteomic Tumor Analysis Consortium head and neck squamous cell carcinoma cohort. The gene expressions were compared for pathways enriched in: (A) Immune vs Hypoxia. Red: enriched in Immune, Blue: enriched in Hypoxia. (B) Im ... Full text Cite

Supplementary Figure S1 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>(A, B) Heatmap of molecular subgroups in two different HNSCC datasets (A) TCGA and (B) CPTAC. RNA expression data was z-normalized, each row represents a single gene in the hypoxia-immune signature gene list, each column represents a patie ... Full text Cite

FIGURE 1 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Molecular classification and validation of hypoxia-immune signature in HNSCC. <b>A,</b> Heatmap of molecular subgroups in the Moffitt (<i>n</i> = 228) HNSCC cohort. RNA expression data were z-normalized, each row re ... Full text Cite

Supplementary Figure S3 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Heatmap of molecular subgroups in MCC18754 (n=48). RNA expression data was z-normalized, each row represents a single gene in the Hypoxia-Immune signature gene list, each column represents a patient sample. Samples were reordered according ... Full text Cite

Supplementary Figure S2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>(A, B) Representative mIHC images showing staining of nuclei (blue), tumor cell (orange - PCK) and selected immune checkpoint markers in each molecular subgroup. (A) Images show four lymphoid markers - CD3+ T-cells (Green), CD8+ cytotoxic ... Full text Cite

Data from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <div><p>Head and neck squamous cell carcinoma (HNSCC) has one of the most hypoxic and immunosuppressive tumor microenvironments (TME) among solid tumors. However, there is no proven therapeutic strategy to remodel the TME to be less hyp ... Full text Cite

FIGURE 2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Hypoxia subgroup has immunosuppressive TME. Boxplots showing cell counts distribution of different immune markers CAIX<sup>+</sup> cells representing hypoxia marker (<b>A</b>), CD3<sup>+</sup> T cells (& ... Full text Cite

FIGURE 3 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>GSEA of hallmark pathways in TCGA and Moffitt cohorts. TCGA (<b>A–C</b>) and Moffitt head and neck squamous cell carcinoma (<b>D–F</b>) cohorts. The gene expressions were compared for pathways enriched in: (<b&gt ... Full text Cite

FIGURE 2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Hypoxia subgroup has immunosuppressive TME. Boxplots showing cell counts distribution of different immune markers CAIX<sup>+</sup> cells representing hypoxia marker (<b>A</b>), CD3<sup>+</sup> T cells (& ... Full text Cite

FIGURE 5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Cetuximab treatment benefits Hypoxia subgroup. <b>A,</b> Heatmap of gene expression data from pre- and post-cetuximab (CTX) treated patient samples. RNA expression data (GSE109756) was z-normalized, each row represents a single ... Full text Cite

Supplementary Table S6 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S6. Core enriched genes within the Hypoxia signature</p> ... Full text Cite

Supplementary Table S6 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S6. Core enriched genes within the Hypoxia signature</p> ... Full text Cite

Supplementary Table S4 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S4. TME across the Immune, Mixture and Hypoxia subgroups</p> ... Full text Cite

Supplementary Table S5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S5. Immune profile of the primary and recurrent tumors in Moffitt HNSCC cohort</p> ... Full text Cite

Supplementary Table S4 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S4. TME across the Immune, Mixture and Hypoxia subgroups</p> ... Full text Cite

Supplementary Table S8 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S8. Hypoxia-Immune classification of Schmitz et al., window-of-opportunity trial (GSE109756)</p> ... Full text Cite

TABLE 2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Disease control given pembrolizumab or nivolumab monotherapy in Moffitt retrospective study cohort</p> ... Full text Cite

Supplementary Table S8 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S8. Hypoxia-Immune classification of Schmitz et al., window-of-opportunity trial (GSE109756)</p> ... Full text Cite

Supplementary Figure S6 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>TIMEx scores for the Immune gene signature among the 15 patients classified into the Hypoxia, Mixture and Immune subgroups.</p> ... Full text Cite

TABLE 2 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Disease control given pembrolizumab or nivolumab monotherapy in Moffitt retrospective study cohort</p> ... Full text Cite

Supplementary Table S5 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S5. Immune profile of the primary and recurrent tumors in Moffitt HNSCC cohort</p> ... Full text Cite

Supplementary Table S7 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S7. Core enriched genes in the TGF-β signaling</p> ... Full text Cite

Supplementary Table S7 from EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma

Other · May 22, 2023 <p>Supplementary Table S7. Core enriched genes in the TGF-β signaling</p> ... Full text Cite

Supplementary Figure S4 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>(A-C) Clinical Proteomic Tumor Analysis Consortium head and neck squamous cell carcinoma cohort. The gene expressions were compared for pathways enriched in: (A) Immune vs Hypoxia. Red: enriched in Immune, Blue: enriched in Hypoxia. (B) Im ... Full text Cite

Supplementary Figure S1 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>(A, B) Heatmap of molecular subgroups in two different HNSCC datasets (A) TCGA and (B) CPTAC. RNA expression data was z-normalized, each row represents a single gene in the hypoxia-immune signature gene list, each column represents a patie ... Full text Cite

Supplementary Figure S5 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Protein network analysis of core-enriched genes within the hypoxia signature and TGF-β signaling from GSEA analysis. Clustering was performed using the STRING database. Three main clusters are depicted: hypoxia (blue color), TGF-β (green c ... Full text Cite

Supplementary Figure S6 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>TIMEx scores for the Immune gene signature among the 15 patients classified into the Hypoxia, Mixture and Immune subgroups.</p> ... Full text Cite

Supplementary Figure S3 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Heatmap of molecular subgroups in MCC18754 (n=48). RNA expression data was z-normalized, each row represents a single gene in the Hypoxia-Immune signature gene list, each column represents a patient sample. Samples were reordered according ... Full text Cite

Supplementary Figure S2 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>(A, B) Representative mIHC images showing staining of nuclei (blue), tumor cell (orange - PCK) and selected immune checkpoint markers in each molecular subgroup. (A) Images show four lymphoid markers - CD3+ T-cells (Green), CD8+ cytotoxic ... Full text Cite

Supplementary Figure S4 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>(A-C) Clinical Proteomic Tumor Analysis Consortium head and neck squamous cell carcinoma cohort. The gene expressions were compared for pathways enriched in: (A) Immune vs Hypoxia. Red: enriched in Immune, Blue: enriched in Hypoxia. (B) Im ... Full text Cite

Supplementary Figure S3 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Heatmap of molecular subgroups in MCC18754 (n=48). RNA expression data was z-normalized, each row represents a single gene in the Hypoxia-Immune signature gene list, each column represents a patient sample. Samples were reordered according ... Full text Cite

Supplementary Figure S6 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>TIMEx scores for the Immune gene signature among the 15 patients classified into the Hypoxia, Mixture and Immune subgroups.</p> ... Full text Cite

Supplementary Figure S5 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Protein network analysis of core-enriched genes within the hypoxia signature and TGF-β signaling from GSEA analysis. Clustering was performed using the STRING database. Three main clusters are depicted: hypoxia (blue color), TGF-β (green c ... Full text Cite

Supplementary Figure S2 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>(A, B) Representative mIHC images showing staining of nuclei (blue), tumor cell (orange - PCK) and selected immune checkpoint markers in each molecular subgroup. (A) Images show four lymphoid markers - CD3+ T-cells (Green), CD8+ cytotoxic ... Full text Cite

Supplementary Figure S1 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>(A, B) Heatmap of molecular subgroups in two different HNSCC datasets (A) TCGA and (B) CPTAC. RNA expression data was z-normalized, each row represents a single gene in the hypoxia-immune signature gene list, each column represents a patie ... Full text Cite

Data from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <div>Abstract<p>Head and neck squamous cell carcinoma (HNSCC) has one of the most hypoxic and immunosuppressive tumor microenvironments (TME) among solid tumors. However, there is no proven therapeutic strategy to remodel the TME to be ... Full text Cite

Supplementary Table S5 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Supplementary Table S5. Immune profile of the primary and recurrent tumors in Moffitt HNSCC cohort</p> ... Full text Cite

Supplementary Table S8 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Supplementary Table S8. Hypoxia-Immune classification of Schmitz et al., window-of-opportunity trial (GSE109756)</p> ... Full text Cite

Supplementary Table S5 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Supplementary Table S5. Immune profile of the primary and recurrent tumors in Moffitt HNSCC cohort</p> ... Full text Cite

Supplementary Table S8 from Epidermal growth factor receptor inhibition by cetuximab modulates hypoxia and interferon response genes in head and neck squamous cell carcinoma

Other · May 4, 2023 <p>Supplementary Table S8. Hypoxia-Immune classification of Schmitz et al., window-of-opportunity trial (GSE109756)</p> ... Full text Cite

EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma.

Journal Article Cancer Res Commun · May 2023 UNLABELLED: Head and neck squamous cell carcinoma (HNSCC) has one of the most hypoxic and immunosuppressive tumor microenvironments (TME) among solid tumors. However, there is no proven therapeutic strategy to remodel the TME to be less hypoxic and proinfl ... Full text Link to item Cite

Bcl11b sustains multipotency and restricts effector programs of intestinal-resident memory CD8+ T cells.

Journal Article Sci Immunol · April 28, 2023 The networks of transcription factors (TFs) that control intestinal-resident memory CD8+ T (TRM) cells, including multipotency and effector programs, are poorly understood. In this work, we investigated the role of the TF Bcl11b in TRM cells during infecti ... Full text Link to item Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 4 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 4 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by tumor and participant characteristics</p> ... Full text Cite

Supplemental Table 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 1 shows the correlations of percentages of the markers in the tumor.</p> ... Full text Cite

Data from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <div>AbstractBackground:<p>Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ... Full text Cite

Supplemental Table 3 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 3 shows case characteristics included on tissue microarrays in NHS and NHSII</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Table 5 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 5 shows beta binomial models, odds ratios and 95% confidence intervals for marker positivity in the tumor, by population characteristics</p> ... Full text Cite

Supplemental Table 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Table 2 shows the distribution of presence/absence of percentage of the marker in the tumor, by age of sample for type I and type II tumors</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 1 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Figure 1 provides representative images from the T cell panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Supplemental Figure 2 from Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies

Other · April 12, 2023 <p>Supplemental Figure 2 provides representative images from the immune checkpoint panel for high-grade serous, endometrioid, clear cell, and mucinous tumors.</p> ... Full text Cite

Abstract 3008: Association between distress and the tumor immune microenvironment in women with ovarian cancer

Conference Cancer Research · April 4, 2023 AbstractVarious forms of distress, most notably depression, increase ovarian cancer risk. Prior work suggests depression can lead to systemic immune suppression; moreover, after ovarian cancer diagnosis, ong ... Full text Cite

Abstract 1186: Contraception and ovarian cancer risk by tumor immune profiles

Conference Cancer Research · April 4, 2023 AbstractIntroduction: An estimated 38 million US women currently use contraception, a critical component of women’s health. Yet, the impact of changing contraceptive types and patterns of use on ovarian canc ... Full text Cite

Abstract 3017: Breastfeeding and ovarian cancer risk by tumor immune profiles

Conference Cancer Research · April 4, 2023 AbstractIntroduction: Breastfeeding is associated with decreased ovarian cancer risk, yet the biological mechanisms are not fully understood. We conducted an agnostic investigation of tumor immune profiles t ... Full text Cite

Supplementary Data from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures

Other · March 31, 2023 Supplementary Data from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures ... Full text Cite

Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures

Other · March 31, 2023 Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures ... Full text Cite

Supplementary Data from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures

Other · March 31, 2023 Supplementary Data from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures ... Full text Cite

Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures

Other · March 31, 2023 Supplementary Figure from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures ... Full text Cite

Data from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures

Other · March 31, 2023 <div>Abstract<p>DNA methylation signatures in tumors could serve as reliable biomarkers that are accessible in archival tissues for tracking the epigenetic dynamics shaped by both cancer cells and the tumor microenvironment. However, gi ... Full text Cite

Data from Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures

Other · March 31, 2023 <div>Abstract<p>DNA methylation signatures in tumors could serve as reliable biomarkers that are accessible in archival tissues for tracking the epigenetic dynamics shaped by both cancer cells and the tumor microenvironment. However, gi ... Full text Cite

Dichotomous Nitric Oxide-Dependent Post-Translational Modifications of STAT1 Are Associated with Ipilimumab Benefits in Melanoma.

Journal Article Cancers (Basel) · March 14, 2023 Although Ipilimumab (anti-CTLA-4) is FDA-approved for stage III/IV melanoma adjuvant treatment, it is not used clinically in first-line therapy, given the superior relapse-free survival (RFS)/toxicity benefits of anti-PD-1 therapy. However, it is important ... Full text Link to item Cite

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects.

Journal Article J Immunother Cancer · February 2023 BACKGROUND: Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies. METHODS: We perform ... Full text Link to item Cite

Lifetime Exposure to Cigarette Smoke and Risk of Ovarian Cancer by T-cell Tumor Immune Infiltration.

Journal Article Cancer Epidemiol Biomarkers Prev · January 9, 2023 BACKGROUND: Exposure to cigarette smoke, particularly in early life, is modestly associated with ovarian cancer risk and may impact systemic immunity and the tumor immune response. However, no studies have evaluated whether cigarette smoke exposure impacts ... Full text Link to item Cite

Neglected no more: B cell-mediated anti-tumor immunity.

Journal Article Semin Immunol · January 2023 Immuno-oncology has traditionally focused on the cellular arm of the adaptive immune response, while attributing tumor-promoting activity to humoral responses in tumor-bearing hosts. This view stems from mouse models that do not necessarily recapitulate th ... Full text Link to item Cite

Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment.

Journal Article Cancer Immunol Res · December 2, 2022 Fragility of regulatory T (Treg) cells manifested by the loss of neuropilin-1 (NRP1) and expression of IFNγ undermines the immune suppressive functions of Treg cells and contributes to the success of immune therapies against cancers. Intratumoral Treg cell ... Full text Link to item Cite

Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors.

Journal Article Immunol Invest · November 2022 CAR T-cell therapy has transformed the treatment of hematological malignancies of the B cell lineage. However, the quest to fulfil the same promise for solid tumors is still in its infancy. This review summarizes some of the challenges that the field is tr ... Full text Link to item Cite

Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses.

Journal Article Cancer Cell · October 10, 2022 Activation of unfolded protein responses (UPRs) in cancer cells undergoing endoplasmic reticulum (ER) stress promotes survival. However, how UPR in tumor cells impacts anti-tumor immune responses remains poorly described. Here, we investigate the role of t ... Full text Link to item Cite

Reduced Satb1 expression predisposes CD4+ T conventional cells to Treg suppression and promotes transplant survival.

Journal Article Proc Natl Acad Sci U S A · October 4, 2022 Limiting CD4+ T cell responses is important to prevent solid organ transplant rejection. In a mouse model of costimulation blockade-dependent cardiac allograft tolerance, we previously reported that alloreactive CD4+ conventional T cells (Tconvs) develop d ... Full text Link to item Cite

Protocol for the isolation of CD8+ tumor-infiltrating lymphocytes from human tumors and their characterization by single-cell immune profiling and multiome.

Journal Article STAR Protoc · September 16, 2022 Understanding the heterogenicity of tumor-infiltraing lymphocyte (TIL) populations and the immunobiology in human cancer is a key to establish efficient immunotherapies. Here, we have established a protocol for the characterization of CD8+ TILs in tumors b ... Full text Link to item Cite

Belly Fat Weakens Immune Fitness.

Journal Article Cancer Discov · August 5, 2022 Much work has been done to reduce cancer immunosuppression through inhibiting soluble proteins, surface molecules, and suppressive cells. This article shows an important role for the lipid lysophosphatidic acid, whose suppression shows promise as a novel c ... Full text Link to item Cite

Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.

Journal Article Mol Cancer Ther · July 5, 2022 Although chimeric antigen receptor (CAR)-expressing T cells have proven success in hematologic malignancies, their effectiveness in solid tumors has been largely unsuccessful thus far. We found that some olfactory receptors are expressed in a variety of so ... Full text Link to item Cite

Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.

Journal Article Cancer Res · June 6, 2022 UNLABELLED: BRCA1-mediated homologous recombination is an important DNA repair mechanism that is the target of FDA-approved PARP inhibitors, yet details of BRCA1-mediated functions remain to be fully elucidated. Similarly, immune checkpoint molecules are t ... Full text Link to item Cite

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males.

Journal Article J Transl Med · June 3, 2022 BACKGROUND: We hypothesized that a gender difference in clinical response may exist to adjuvant CTLA4 blockade with ipilimumab versus high-dose IFNα (HDI). We investigated differences in candidate immune biomarkers in the circulation and tumor microenviron ... Full text Link to item Cite

T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.

Journal Article J Immunother Cancer · June 2022 BACKGROUND: T cell receptor (TCR) signaling profile is a fundamental property that underpins both adaptive and innate immunity in the host. Despite its potential clinical relevance, the TCR repertoire in peripheral blood has not been thoroughly explored fo ... Full text Link to item Cite

Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.

Journal Article Cancer Cell · May 9, 2022 Despite repeated associations between T cell infiltration and outcome, human ovarian cancer remains poorly responsive to immunotherapy. We report that the hallmarks of tumor recognition in ovarian cancer-infiltrating T cells are primarily restricted to tis ... Full text Link to item Cite

Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma.

Journal Article Cancer Epidemiol Biomarkers Prev · May 4, 2022 BACKGROUND: Tumor-infiltrating lymphocytes (TIL) confer a survival benefit among patients with ovarian cancer; however, little work has been conducted in racially diverse cohorts. METHODS: The current study investigated racial differences in the tumor immu ... Full text Link to item Cite

Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents.

Journal Article Int J Mol Sci · May 4, 2022 The interaction between tumor surface-expressed PDL1 and immune cell PD1 for the evasion of antitumor immunity is well established and is targeted by FDA-approved anti-PDL1 and anti-PD1 antibodies. Nonetheless, recent studies highlight the immunopathogenic ... Full text Link to item Cite

Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures.

Journal Article Cancer Res · May 3, 2022 UNLABELLED: DNA methylation signatures in tumors could serve as reliable biomarkers that are accessible in archival tissues for tracking the epigenetic dynamics shaped by both cancer cells and the tumor microenvironment. However, given the ultrahigh dimens ... Full text Link to item Cite

Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.

Journal Article Cancer Discov · May 2, 2022 ABSTRACT: Cutaneous T-cell lymphoma (CTCL) is a rare cancer of skin-homing T cells. A subgroup of patients develops large cell transformation with rapid progression to an aggressive lymphoma. Here, we investigated the transformed CTCL (tCTCL) tumor ecosyst ... Full text Link to item Cite

Spontaneous class-switched antibody responses at endometrial cancer tumor bed drives superior patients’ outcome

Conference The Journal of Immunology · May 1, 2022 AbstractThe role of humoral responses in endometrial cancer remains insufficiently investigated. Using a cohort of 107 patients with different histological subtypes of endometrial carcinoma, we report that c ... Full text Cite

Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T-cells

Conference The Journal of Immunology · May 1, 2022 AbstractDespite repeated associations between T-cell infiltration and patient outcome, human ovarian cancer remains poorly responsive to immunotherapy. We report that hallmarks of tumor recognition in ovaria ... Full text Cite

CAR T cells targeting Olfactory Receptor OR2H1 are an effective immunotherapeutic option in human epithelial tumors

Conference The Journal of Immunology · May 1, 2022 AbstractChimeric antigen receptor (CAR) T cells have been successful for hematological malignancies, but so far showed limited efficiency against solid tumors. Olfactory receptors are expressed in a variety ... Full text Cite

Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.

Journal Article Genome Med · March 29, 2022 BACKGROUND: Recent studies show that human gut microbial composition can determine whether a patient is a responder or non-responder to immunotherapy but have not identified a common microbial signal shared by responding patients. The functional relationsh ... Full text Link to item Cite

IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer.

Journal Article Cancer Res · March 1, 2022 UNLABELLED: Recent studies suggest that B cells could play an important role in the tumor microenvironment. However, the role of humoral responses in endometrial cancer remains insufficiently investigated. Using a cohort of 107 patients with different hist ... Full text Link to item Cite

TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.

Journal Article Immunity · January 11, 2022 The immune checkpoint receptor PD-1 on T follicular helper (Tfh) cells promotes Tfh:B cell interactions and appropriate positioning within tissues. Here, we examined the impact of regulation of PD-1 expression by the genomic organizer SATB1 on Tfh cell dif ... Full text Link to item Cite

Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center.

Journal Article Leuk Lymphoma · January 2022 Sézary syndrome (SS) is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma, with a median overall survival (OS) rate of 2-4 years. Few studies have described the clinical outcome of SS patients since 2012. We retrospectively analyzed 70 pa ... Full text Link to item Cite

Abstract PO-232: Racial differences in the tumor immune landscape and survival of high-grade serous ovarian carcinoma

Conference Cancer Epidemiology, Biomarkers & Prevention · January 1, 2022 AbstractA survival benefit has been consistently observed for tumor infiltrating lymphocytes (TILs) among ovarian cancer patients; however, prior studies consist of predominantly white women and little work ... Full text Cite

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.

Journal Article PLoS One · 2022 The distribution of Endometrial Cancer (EC)-related deaths is uneven among the morphologic subtypes of EC. Serous Cancer (SC) makes 10% of all EC and accounts for 40% of EC-related deaths. We investigated expression of selected genes involved in epigenetic ... Full text Link to item Cite

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.

Journal Article J Immunother Cancer · January 2022 BACKGROUND: Melanoma of unknown primary (MUP) represents a poorly understood group of patients both clinically and immunologically. We investigated differences in prognosis and candidate immune biomarkers in patients with unknown compared with those with k ... Full text Link to item Cite

TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization.

Journal Article J Immunother Cancer · January 2022 BACKGROUND: T cell immunoglobulin and mucin domain containing-3 (TIM-3) blocking antibodies are currently being evaluated in clinical trials for solid and hematological malignancies. Despite its identification on T cells, TIM-3 is predominantly expressed b ... Full text Link to item Cite

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma.

Journal Article Front Oncol · 2022 Optimal management of locally advanced vaginal mucosal melanoma is poorly understood because of its rarity and unique biology. Patients have a poor prognosis despite aggressive management approaches including pelvic exenteration and adjuvant radiation that ... Full text Link to item Cite

88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males

Conference Journal for ImmunoTherapy of Cancer · November 2021 BackgroundSex differences in tumor immunity and response to immunotherapy were shown in murine models and descriptive analyses from recent clinical trials. We recently reported that female gender is a favorable pr ... Full text Cite

87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known

Conference Journal for ImmunoTherapy of Cancer · November 2021 BackgroundWe recently reported data supporting the unknown primary status as a potentially distinct prognostic group among high-risk melanoma patients treated with ipilimumab and high dose interferon-alfa (HDI) in ... Full text Cite

B cells and cancer.

Journal Article Cancer Cell · October 11, 2021 Tumor-infiltrating B cells complement T cell-mediated antitumor immunity. A panel of experts share their views on the complexity of B cells within the tumor microenvironment, the variety of mechanisms by which these cells control tumor growth, their organi ... Full text Link to item Cite

Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.

Journal Article Nat Rev Urol · September 2021 The advent of immune checkpoint inhibition (ICI) has transformed the treatment paradigm for bladder cancer. However, despite the success of ICI in other tumour types, the majority of ICI-treated patients with bladder cancer failed to respond. The lack of e ... Full text Link to item Cite

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

Journal Article Nat Med · August 2021 Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs adm ... Full text Link to item Cite

Determinants of response to checkpoint inhibition in ovarian cancer.

Conference Journal of Clinical Oncology · May 20, 2021 e17538 Background: Despite evidence that ovarian cancer (OC) is an immunogenic disease, single-agent checkpoint inhibitors have shown limited response. A clinical trial was conducted evaluating dose-dense paclitaxel and pembroliz ... Full text Cite

Somatic mutations predict immune-related adverse events (irAEs) and survival following CTLA4 blockade in melanoma patients.

Conference Journal of Clinical Oncology · May 20, 2021 e21584 Background: Predicting immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs) as well as the likelihood of clinical benefit is an area of great interest. irAEs have been associated with cl ... Full text Cite

Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.

Journal Article Blood · May 13, 2021 Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with treatme ... Full text Link to item Cite

Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.

Journal Article Mol Ther · April 7, 2021 HER2 breast cancer (BC) remains a significant problem in patients with locally advanced or metastatic BC. We investigated the relationship between T helper 1 (Th1) immune response and the proteasomal degradation pathway (PDP), in HER2-sensitive and -resist ... Full text Link to item Cite

Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.

Journal Article Cancer Epidemiol Biomarkers Prev · April 2021 BACKGROUND: Chronic inflammation is a well-established mechanism of ovarian carcinogenesis; however, the specific immunogenic processes influencing ovarian tumor development remain unclear. In a case-control study nested within the Nurses' Health Study (NH ... Full text Link to item Cite

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.

Journal Article J Immunother Cancer · April 2021 BACKGROUND: Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in <30% of patients. Interleukin (IL)-2/αIL-2 complexes (IL-2c) that preferentially target IL-2 receptor β (CD122) augment CD8+ anti ... Full text Link to item Cite

IgA transcytosis and antigen recognition govern ovarian cancer immunity.

Journal Article Nature · March 2021 Most ovarian cancers are infiltrated by prognostically relevant activated T cells1-3, yet exhibit low response rates to immune checkpoint inhibitors4. Memory B cell and plasma cell infiltrates have previously been associated with better outcomes in ovarian ... Full text Link to item Cite

The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer.

Conference Journal of Clinical Oncology · February 20, 2021 466 Background: Adaptive anti-tumor immunity can be orchestrated by lymph node-like immune cell aggregates within the tumor microenvironment (TME) called tertiary lymphoid structures (TLSs). TLSs are postulated to be the gateway ... Full text Cite

Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.

Journal Article Int J Radiat Oncol Biol Phys · February 1, 2021 PURPOSE: Consolidative thoracic radiation therapy (TRT) has been shown to improve outcomes for patients with extensive stage small cell lung cancer. We hypothesized that the addition of ipilimumab (IPI) and nivolumab (NIVO) after TRT would improve outcomes ... Full text Link to item Cite

Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.

Journal Article J Clin Invest · February 1, 2021 Cutaneous T cell lymphoma (CTCL) has a poorly understood etiology and no known cure. Using conditional knockout mice, we found that ablation of the genomic organizer special AT-rich sequence-binding protein 1 (Satb1) caused malignant transformation of matu ... Full text Link to item Cite

Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma.

Journal Article Mol Carcinog · February 2021 Prognosis for patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) remains poor. Development of more effective and less toxic targeted therapies is necessary for HNSCC patients. Checkpoint kinase 1 (CHK1) plays a vital ro ... Full text Link to item Cite

The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community.

Journal Article Front Immunol · 2021 Recent years have witnessed a dramatic rise in interest towards cancer epitopes in general and particularly neoepitopes, antigens that are encoded by somatic mutations that arise as a consequence of tumorigenesis. There is also an interest in the specific ... Full text Link to item Cite

The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures.

Journal Article Front Immunol · 2021 There is emerging evidence that the adaptive anti-tumor activity may be orchestrated by secondary lymphoid organ-like aggregates residing in the tumor microenvironment. Known as tertiary lymphoid structures, these lymphoid aggregates serve as key outposts ... Full text Link to item Cite

Wide and deep learning for automatic cell type identification.

Journal Article Comput Struct Biotechnol J · 2021 Cell type classification is an important problem in cancer research, especially with the advent of single cell technologies. Correctly identifying cells within the tumor microenvironment can provide oncologists with a snapshot of how a patient's immune sys ... Full text Link to item Cite

CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.

Journal Article Cancer Res · November 15, 2020 The IL2 receptor (IL2R) is an attractive cancer immunotherapy target that controls immunosuppressive T regulatory cells (Treg) and antitumor T cells. Here we used IL2Rβ-selective IL2/anti-IL2 complexes (IL2c) to stimulate effector T cells preferentially in ... Full text Link to item Cite

280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients

Conference Regular and young investigator award abstracts · November 2020 Full text Cite

Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer.

Journal Article Int J Cancer · October 15, 2020 The microenvironment of pancreatic cancer adenocarcinoma (PDAC) is highly desmoplastic with distinct tumor-restraining and tumor-promoting fibroblast subpopulations. Re-education rather than indiscriminate elimination of these fibroblasts has emerged as a ... Full text Link to item Cite

Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells.

Journal Article Cell Metab · September 1, 2020 Dysregulated metabolism is a key driver of maladaptive tumor-reactive T lymphocytes within the tumor microenvironment. Actionable targets that rescue the effector activity of antitumor T cells remain elusive. Here, we report that the Sirtuin-2 (Sirt2) NAD+ ... Full text Link to item Cite

PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.

Journal Article Int J Gynecol Pathol · September 2020 Management options are limited in advanced or recurrent cervical carcinoma. The Food and Drug Administration has recently approved programed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) inhibitors for the treatment of advanced PD-L1 positive cervical cancer. We ... Full text Link to item Cite

The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma.

Journal Article Cancer Epidemiol Biomarkers Prev · September 2020 BACKGROUND: MUC16 is a mucin marker that is frequently mutated in melanoma, but whether MUC16 mutations could be useful as a surrogate biomarker for tumor mutation burden (TMB) remains unclear. METHODS: This study rigorously evaluates the MUC16 mutation as ... Full text Link to item Cite

BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.

Journal Article Science · August 21, 2020 Gamma delta (γδ) T cells infiltrate most human tumors, but current immunotherapies fail to exploit their in situ major histocompatibility complex-independent tumoricidal potential. Activation of γδ T cells can be elicited by butyrophilin and butyrophilin-l ... Full text Link to item Cite

Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial

Conference Cancer Research · August 15, 2020 AbstractStudy Objectives: A hallmark of tumor infiltrating lymphocytes (TIL) in melanoma is the potential for a complete response (CR) which can last for decades. This long-lived effect is attributed to pers ... Full text Cite

Abstract 5719: Tumor-suppressive stromal activity of pro-fibrogenic microRNA-21 in initiation and progression of K-Ras-driven mouse models of pancreatic cancer

Conference Cancer Research · August 15, 2020 AbstractPancreatic ductal adenocarcinoma (PDAC) is a recalcitrant and lethal disease with an overall 5-year survival rate of less than 8%. The abundance and heterogeneity of cancer-associated fibroblasts (CA ... Full text Cite

Kindlin-3 gives patrolling monocytes a strong grip.

Journal Article J Leukoc Biol · June 2020 Discussion on the role of Kindlin-3 in the capacity of nonclassical monocytes to prevent malignant colonization of vascularized tissues by ensuring effective endothelial adhesion. ... Full text Link to item Cite

Humoral immune responses: Unsung heroes of the war on cancer.

Journal Article Semin Immunol · June 2020 Solid cancers progress from primordial lesions through complex interactions between tumor-promoting and anti-tumor immune cell types, ultimately leading to the orchestration of humoral and T cell adaptive immune responses, albeit in an immunosuppressive en ... Full text Link to item Cite

Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.

Journal Article J Immunother Cancer · June 2020 Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with cancer ... Full text Link to item Cite

The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.

Journal Article Immunity · April 14, 2020 The primary mechanisms supporting immunoregulatory polarization of myeloid cells upon infiltration into tumors remain largely unexplored. Elucidation of these signals could enable better strategies to restore protective anti-tumor immunity. Here, we invest ... Full text Link to item Cite

c-Maf: a bad influence in the education of macrophages.

Journal Article J Clin Invest · April 1, 2020 Tumor-associated macrophages (TAMs) represent the most abundant hematopoietic cell type in the solid tumor microenvironment. TAMs drive T cell inhibition, promote angiogenesis, and produce tumor growth factors. Although they can paradoxically exert antitum ... Full text Link to item Cite

Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.

Journal Article Clin Cancer Res · March 15, 2020 PURPOSE: Patients with head and neck squamous cell carcinoma (HNSCC) who actively smoke during treatment have worse survival compared with never-smokers and former-smokers. We hypothesize the poor prognosis in tobacco smokers with HNSCC is, at least in par ... Full text Link to item Cite

Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer.

Journal Article J Immunol · December 15, 2019 Tumor-associated macrophages are major contributors to malignant progression and resistance to immunotherapy, but the mechanisms governing their differentiation from immature myeloid precursors remain incompletely understood. In this study, we demonstrate ... Full text Link to item Cite

AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.

Journal Article Cancer Res · October 1, 2019 Myeloid-derived suppressor cells (MDSC) represent a primary mechanism of immune evasion in tumors and have emerged as a major obstacle for cancer immunotherapy. The immunoinhibitory activity of MDSC is tightly regulated by the tumor microenvironment and oc ... Full text Link to item Cite

Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Journal Article Nat Commun · August 15, 2019 An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Full text Link to item Cite

Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer.

Journal Article J Clin Invest · July 29, 2019 Pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related death and is largely resistant to immunotherapies. The tumor microenvironment, largely composed of heterogeneous myeloid cells, creates a physical, metabolic ... Full text Link to item Cite

Estimation of immune cell content in tumor using single-cell RNA-seq reference data.

Journal Article BMC Cancer · July 19, 2019 BACKGROUND: The rapid development of single-cell RNA sequencing (scRNA-seq) provides unprecedented opportunities to study the tumor ecosystem that involves a heterogeneous mixture of cell types. However, the majority of previous and current studies related ... Full text Link to item Cite

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.

Journal Article Cancer Cell · June 10, 2019 We investigated the role of chemokines in regulating T cell accumulation in solid tumors. CCL5 and CXCL9 overexpression was associated with CD8+ T cell infiltration in solid tumors. T cell infiltration required tumor cell-derived CCL5 and was amplified by ... Full text Link to item Cite

Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.

Conference Journal of Clinical Oncology · May 20, 2019 TPS5596 Background: There is no consistent recommendation for management of metastatic cervical cancer beyond first line therapy with chemotherapy and bevacizumab. Pembrolizumab is now approved for PD-L1 positive or MSI-H/dMMR me ... Full text Cite

Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery.

Journal Article JCO Clin Cancer Inform · April 2019 PURPOSE: Early-stage cancers are routinely treated with surgery followed by radiotherapy (SR). Radiotherapy before surgery (RS) has been widely ignored for some cancers. We evaluate overall survival (OS) and disease-free survival (DFS) with SR and RS for d ... Full text Link to item Cite

Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies.

Journal Article Front Phys · April 2019 Cancer photomedicine offers unique mechanisms for inducing local tumor damage with the potential to stimulate local and systemic anti-tumor immunity. Optically-active nanomedicine offers these features as well as spatiotemporal control of tumor-focused dru ... Full text Link to item Cite

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

Journal Article Nat Commun · March 20, 2019 Understanding the intrinsic mediators that render CD8+ T cells dysfunctional in the tumor microenvironment is a requirement to develop more effective cancer immunotherapies. Here, we report that C/EBP homologous protein (Chop), a downstream sensor of sever ... Full text Link to item Cite

Abstract ES10-3: Blockade of estrogen signaling boosts antitumor immunity by inhibiting tumor-induced pathological myelopoiesis

Conference Cancer Research · February 15, 2019 AbstractAlthough the role of estrogen signaling in the progression of a subset of breast tumors has been underscored by the clinical use of Estrogen Receptor antagonists, how estrogens impact protective anti ... Full text Cite

IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment.

Journal Article Oncoimmunology · 2019 Ovarian cancer is frequently diagnosed as peritoneal carcinomatosis. Unlike other tumor locations, the peritoneal cavity is commonly exposed to gut-breaching and ascending genital microorganisms and has a unique immune environment. IL-33 is a local cytokin ... Full text Link to item Cite

Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse.

Journal Article PLoS One · 2019 BACKGROUND: Epidemiological data suggests that obstructive sleep apnea (OSA) is associated with increased cancer incidence and mortality. We investigate the effects of cyclical intermittent hypoxia (CIH), akin to the underlying pathophysiology of OSA, on l ... Full text Link to item Cite

Satb1 deficiency licenses TFH-differentiation

Conference JOURNAL OF IMMUNOLOGY · 2019 Cite

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Journal Article Clin Cancer Res · November 1, 2018 Purpose: We have shown that the aged microenvironment increases melanoma metastasis, and decreases response to targeted therapy, and here we queried response to anti-PD1.Experimental Design: We analyzed the relationship between age, response to anti-PD1, a ... Full text Open Access Link to item Cite

Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer.

Journal Article Cell · October 18, 2018 Dietary soluble fibers are fermented by gut bacteria into short-chain fatty acids (SCFA), which are considered broadly health-promoting. Accordingly, consumption of such fibers ameliorates metabolic syndrome. However, incorporating soluble fiber inulin, bu ... Full text Link to item Cite

IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.

Journal Article Nature · October 2018 Tumours evade immune control by creating hostile microenvironments that perturb T cell metabolism and effector function1-4. However, it remains unclear how intra-tumoral T cells integrate and interpret metabolic stress signals. Here we report that ovarian ... Full text Link to item Cite

Abstract SY01-02: Blockade of estrogen signaling boosts antitumor immunity by dwindling cancer-promoting myelopoiesis

Conference Cancer Research · July 1, 2018 AbstractAlthough the role of estrogen signaling in the progression of breast tumors and a subset of ovarian cancer patients has been underscored by the clinical use of ER antagonists, how estrogens impact th ... Full text Cite

Abstract 3145: Characterization of novel immune checkpoint receptors within the breast cancer tumor microenvironment

Conference Cancer Research · July 1, 2018 AbstractIntroduction. The interruption of immune checkpoint receptor (ICR)/ligand interaction within the tumor microenvironment has become an important immunotherapy strategy. In breast cancer (BC), neither ... Full text Cite

Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy.

Journal Article J Leukoc Biol · May 2018 Due to their cytotoxic activities, many anticancer drugs cause extensive damage to the intestinal mucosa and have antibiotic activities. Here, we show that cisplatin induces significant changes in the repertoire of intestinal commensal bacteria that exacer ... Full text Link to item Cite

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.

Journal Article Cell Rep · March 27, 2018 ARID1A, a subunit of the SWI/SNF complex, is among the most frequently mutated genes across cancer types. ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCCs), diseases that have no effective therapy. Here, we show that ARID1A mutati ... Full text Link to item Cite

CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.

Journal Article Nat Commun · February 12, 2018 CARM1 is an arginine methyltransferase that asymmetrically dimethylates protein substrates on arginine residues. CARM1 is often overexpressed in human cancers. However, clinically applicable cancer therapeutic strategies based on CARM1 expression remain to ... Full text Link to item Cite

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.

Journal Article Front Immunol · 2018 Acute graft- vs. -host disease (GVHD) is an important cause of morbidity and death after allogeneic hematopoietic cell transplantation (HCT). We identify a new approach to prevent GVHD that impairs monocyte-derived dendritic cell (moDC) alloactivation of T ... Full text Link to item Cite

Imaging Lung Cancer Using Hyperpolarized MRI Technology: A Preliminary Study

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · 2018 Cite

Immunotherapy for Breast Cancer: Current and Future Strategies.

Journal Article Curr Surg Rep · December 2017 PURPOSE OF REVIEW: The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed ... Full text Link to item Cite

Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.

Journal Article Cancer Immunol Res · December 2017 Chimeric antigen receptors (CAR) are synthetic molecules that provide new specificities to T cells. Although successful in treatment of hematologic malignancies, CAR T cells are ineffective for solid tumors to date. We found that the cell-surface molecule ... Full text Link to item Cite

ARID1A-mutated ovarian cancers depend on HDAC6 activity.

Journal Article Nat Cell Biol · August 2017 ARID1A, encoding a subunit of the SWI/SNF chromatin-remodelling complex, is the most frequently mutated epigenetic regulator across all human cancers. ARID1A and TP53 mutations are typically mutually exclusive. Therapeutic approaches that correlate with th ... Full text Link to item Cite

Abstract 3707: Tumor-associated neutrophils with antigen-presenting features in early-stage human lung cancer

Conference Cancer Research · July 1, 2017 AbstractTo date there has been an increasing focus on the interactions between inflammatory myeloid cells and T cells in the tumor microenvironment because cytotoxic anti-tumoral T cells represent the chief ... Full text Cite

SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.

Journal Article Immunity · January 17, 2017 Despite the importance of programmed cell death-1 (PD-1) in inhibiting T cell effector activity, the mechanisms regulating its expression remain poorly defined. We found that the chromatin organizer special AT-rich sequence-binding protein-1 (Satb1) restra ... Full text Link to item Cite

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Journal Article Clin Cancer Res · January 15, 2017 PURPOSE: To define the safety and effectiveness of T cells redirected against follicle-stimulating hormone receptor (FSHR)-expressing ovarian cancer cells. EXPERIMENTAL DESIGN: FSHR expression was determined by Western blotting, immunohistochemistry, and q ... Full text Link to item Cite

Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Journal Article Cancer Discov · January 2017 UNLABELLED: The role of estrogens in antitumor immunity remains poorly understood. Here, we show that estrogen signaling accelerates the progression of different estrogen-insensitive tumor models by contributing to deregulated myelopoiesis by both driving ... Full text Link to item Cite

Targeted Therapy and Immunosuppression in the Tumor Microenvironment.

Journal Article Trends Cancer · January 2017 Small-molecule inhibitors offer great promise for targeting pathways that are specifically deregulated in different tumors. However, such 'targeted' therapies also elicit poorly understood effects on protective antitumor immunity. Given the emerging releva ... Full text Link to item Cite

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Journal Article Cancer Res · December 1, 2016 PD-L1 antibodies produce efficacious clinical responses in diverse human cancers, but the basis for their effects remains unclear, leaving a gap in the understanding of how to rationally leverage therapeutic activity. PD-L1 is widely expressed in tumor cel ... Full text Link to item Cite

BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.

Journal Article Cancer Res · November 1, 2016 The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH ... Full text Link to item Cite

The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.

Journal Article Mol Cell Proteomics · November 2016 Inactivating mutations in ARID1A, which encodes a subunit of the SWI/SNF chromatin-remodeling complex, are found in over half of ovarian clear cell carcinoma cases and more broadly across most types of cancers. To identify ARID1A-dependent changes in intra ... Full text Link to item Cite

Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis.

Journal Article Cancer Res · November 1, 2016 Targeted therapies elicit seemingly paradoxical and poorly understood effects on tumor immunity. Here, we show that the MEK inhibitor trametinib abrogates cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) from human or mouse m ... Full text Link to item Cite

Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.

Journal Article Oncogenesis · October 31, 2016 The gene encoding phosphatidylinositol 3-kinase catalytic subunit α-isoform (PIK3CA, p110α) is frequently activated by mutation in human cancers. Based on detection in some breast cancer precursors, PIK3CA mutations have been proposed to have a role in tum ... Full text Link to item Cite

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Journal Article Cell Rep · September 13, 2016 Restoration of anti-tumor immunity by blocking PD-L1 signaling through the use of antibodies has proven to be beneficial in cancer therapy. Here, we show that BET bromodomain inhibition suppresses PD-L1 expression and limits tumor progression in ovarian ca ... Full text Link to item Cite

Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways.

Journal Article J Mol Biol · August 14, 2016 Along with the discovery of tumor-driven inflammatory pathways, there has been a considerable progress over the past 10years in understanding the mechanisms leading to cancer immunosurveillance and immunoediting. Several regulatory pathways, typically invo ... Full text Link to item Cite

State-of-the-art of regulatory dendritic cells in cancer.

Journal Article Pharmacol Ther · August 2016 Dendritic cells (DCs) with robust immunosuppressive activity are commonly found in the microenvironment of advanced solid tumors. These innate immune cells are generically termed regulatory DCs and include various subsets such as plasmacytoid, conventional ... Full text Link to item Cite

Abstract A02: The origin and role of APC-like hybrid tumor-associated neutrophils in early-stage human lung cancer

Conference Cancer Research · August 1, 2016 AbstractTo date there has been an increasing focus on the interactions between inflammatory myeloid cells and T cells in the tumor microenvironment because cytotoxic anti-tumoral T cells represent the chief ... Full text Cite

Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.

Journal Article Cancer Cell · July 11, 2016 Based on studies in mouse tumor models, granulocytes appear to play a tumor-promoting role. However, there are limited data about the phenotype and function of tumor-associated neutrophils (TANs) in humans. Here, we identify a subset of TANs that exhibited ... Full text Link to item Cite

Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis.

Journal Article Eur J Immunol · July 2016 In experimental autoimmune encephalomyelitis (EAE), intravenous (i.v.) injection of the antigen, myelin oligodendrocyte glycoprotein-derived peptide, MOG35-55 , suppresses disease development, a phenomenon called i.v. tolerance. Galectin-1, an endogenous g ... Full text Link to item Cite

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.

Journal Article Cancer Res · May 1, 2016 Many signal transduction inhibitors are being developed for cancer therapy target pathways that are also important for the proper function of antitumor lymphocytes, possibly weakening their therapeutic effects. Here we show that most inhibitors targeting m ... Full text Link to item Cite

Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors

Chapter · April 1, 2016 Combinatorial use of iron oxide nanoparticles (IONPs) and an alternating magnetic fi eld (AMF) can induce local hyperthermia in tumors in a controlled and uniform manner. Heating B16 primary tumors at 43°C for 30 min activated dendritic cells (DCs) and sub ... Full text Cite

Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells.

Journal Article Cell Rep · February 23, 2016 Special AT-rich sequence-binding protein 1 (Satb1) governs genome-wide transcriptional programs. Using a conditional knockout mouse, we find that Satb1 is required for normal differentiation of conventional dendritic cells (DCs). Furthermore, Satb1 governs ... Full text Link to item Cite

Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.

Journal Article Signal Transduct Target Ther · 2016 As tumor PD-L1 provides signals to anti-tumor PD-1+ T cells that blunt their functions, αPD-1 and αPD-L1 antibodies have been developed as anti-cancer immunotherapies based on interrupting this signaling axis. However, tumor cell-intrinsic PD-L1 signals al ... Full text Link to item Cite

Abstract IA32: Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors

Conference Cancer Immunology Research · January 1, 2016 AbstractHumans are symbiotic organisms in which bacteria outnumber eukaryotic cells in a ratio of 10 to 1. Interactions between commensal microorganisms and immune cells at mucosal surfaces forge the orchest ... Full text Cite

Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies.

Journal Article Immunity · December 15, 2015 Commensal microorganisms influence malignant progression by altering systemic inflammation. New data from two groups (Vétizou et al., 2015; Sivan et al., 2015) indicate that the abundance of specific commensal bacterial species enhances the anti-cancer act ... Full text Link to item Cite

Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes.

Journal Article Proc Natl Acad Sci U S A · November 17, 2015 Telomeric repeat-containing RNA (TERRA) has been identified as a telomere-associated regulator of chromosome end protection. Here, we report that TERRA can also be found in extracellular fractions that stimulate innate immune signaling. We identified extra ... Full text Link to item Cite

Myristoylated p110α Causes Embryonic Death Due to Developmental and Vascular Defects.

Journal Article Open Life Sci · October 2015 The phosphatidylinositol 3-kinase (PI3K) signaling pathway regulates many important cellular functions. The functional impact of deregulating the PIK3CA gene, encoding the p110α catalytic subunit of PI3K, is validated by frequent gain of function mutations ... Full text Link to item Cite

Abstract A66: Tumor-associated neutrophils in early stage human lung cancer are not immunosuppressive, but exhibit an inflammatory phenotype and provide accessory signals for T cell activation

Conference Cancer Immunology Research · October 1, 2015 AbstractTumor-recruited myeloid cells represent a significant portion of inflammatory cells within the tumor microenvironment and influence nearly all steps of tumor progression. Although tumor-associated ne ... Full text Cite

Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model.

Journal Article Vaccine · August 20, 2015 Identifying new molecular adjuvants that elicit effective vaccine-induced CD8(+) T cell immunity may be critical for the elimination of many challenging diseases including Tuberculosis, HIV and cancer. Here, we report that co-administration of molecular ad ... Full text Link to item Cite

TLR5 signaling, commensal microbiota and systemic tumor promoting inflammation: the three parcae of malignant progression.

Journal Article Oncoimmunology · August 2015 We have reported that TLR5-mediated recognition of commensal microbiota modulates systemic tumor-promoting inflammation and malignant progression of tumors at distal locations. Approximately 7-10% of the general population harbors a deleterious single nucl ... Full text Link to item Cite

ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.

Journal Article Cell · June 18, 2015 Dendritic cells (DCs) are required to initiate and sustain T cell-dependent anti-cancer immunity. However, tumors often evade immune control by crippling normal DC function. The endoplasmic reticulum (ER) stress response factor XBP1 promotes intrinsic tumo ... Full text Link to item Cite

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Journal Article Nat Med · March 2015 The gene encoding ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently have no effective therapy. To date, clinically appli ... Full text Link to item Cite

Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation.

Journal Article Cancer Cell · January 12, 2015 The dominant TLR5(R392X) polymorphism abrogates flagellin responses in >7% of humans. We report that TLR5-dependent commensal bacteria drive malignant progression at extramucosal locations by increasing systemic IL-6, which drives mobilization of myeloid-d ... Full text Link to item Cite

Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity.

Journal Article Oncoscience · 2015 Recent studies have demonstrated that the commensal microbiota are indispensable for the maintenance of immune homeostasis, orchestration of immune responses against pathogens and most recently during cancer immunotherapy and malignant progression of extra ... Full text Link to item Cite

The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds.

Chapter · 2015 During tumor progression, alterations within the systemic tumor environment, or macroenvironment, result in the promotion of tumor growth, tumor invasion to distal organs, and eventual metastatic disease. Distally produced hormones, commensal microbiota re ... Full text Link to item Cite

Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.

Journal Article J Clin Invest · December 2014 Infiltrating inflammatory cells are highly prevalent within the tumor microenvironment and mediate many processes associated with tumor progression; however, the contribution of specific populations remains unclear. For example, the nature and function of ... Full text Link to item Cite

Mesothelin expression is associated with poor outcomes in breast cancer.

Journal Article Breast Cancer Res Treat · October 2014 Mesothelin is a potential therapeutic target and prognostic marker in breast cancer. However, results on its prognostic value in breast cancer have been equivocal and warranted further evaluation. We analyzed clinical data from two breast cancer patient co ... Full text Link to item Cite

Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression.

Journal Article Immunity · September 18, 2014 Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead box protein P1 (Foxp1), which prevents CD8⁺ T ... Full text Link to item Cite

Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors.

Journal Article Nanomedicine · August 2014 UNLABELLED: Combinatorial use of iron oxide nanoparticles (IONPs) and an alternating magnetic field (AMF) can induce local hyperthermia in tumors in a controlled and uniform manner. Heating B16 primary tumors at 43°C for 30 min activated dendritic cells (D ... Full text Link to item Cite

Mesothelin expression as a predictive biomarker of breast cancer outcomes.

Conference Journal of Clinical Oncology · May 20, 2014 Full text Cite

Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer.

Journal Article J Vis Exp · March 26, 2014 Breast cancer is a heterogeneous disease involving complex cellular interactions between the developing tumor and immune system, eventually resulting in exponential tumor growth and metastasis to distal tissues and the collapse of anti-tumor immunity. Many ... Full text Link to item Cite

A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis.

Journal Article J Cell Physiol · January 2014 Although recent evidence indicates that several chemokines and defensins, well-known as inflammatory mediators, are expressed in the male and female reproductive tracts, the location and functional significance of chemokine networks in sperm physiology and ... Full text Link to item Cite

Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer.

Journal Article Front Immunol · December 10, 2013 A common characteristic of solid tumors is the pathological recruitment of immunosuppressive myeloid cells, which in certain tumors includes dendritic cells (DCs). DCs are of particular interest in the field of cancer immunotherapy because they induce pote ... Full text Link to item Cite

Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer.

Journal Article Hum Pathol · November 2013 Fibroblast activation protein (FAP) has long been known to be expressed in the stroma of breast cancer. However, very little is known if the magnitude of FAP expression within the stroma may have a prognostic value and reflect the heterogeneous biology of ... Full text Link to item Cite

Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.

Journal Article Cancer Res · July 1, 2013 Reversing tumor-associated immunosuppression seems necessary to stimulate effective therapeutic immunity against lethal epithelial tumors. Here, we show this goal can be addressed using cps, an avirulent, nonreplicating uracil auxotroph strain of the paras ... Full text Link to item Cite

Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.

Journal Article Cell Cycle · July 1, 2013 Inhibitors of EZH2 methyltransferase activity have been demonstrated to selectively suppress the growth of diffused large B cell lymphoma (DLBCL) cells with gain-of-function mutations in EZH2, while exhibiting very limited effects on the growth of DLBCL ce ... Full text Link to item Cite

Reprogramming immune responses via microRNA modulation.

Journal Article Microrna Diagn Ther · April 26, 2013 It is becoming increasingly clear that there are unique sets of miRNAs that have distinct governing roles in several aspects of both innate and adaptive immune responses. In addition, new tools allow selective modulation of the expression of individual miR ... Full text Link to item Cite

Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy.

Journal Article Integr Biol (Camb) · January 2013 Nanotechnology has great potential to produce novel therapeutic strategies that target malignant cells through the ability of nanoparticles to get access to and be ingested by living cells. However its specificity for accumulation in tumors, which is the k ... Full text Link to item Cite

Targeted molecular therapies for cancer: collateral damage?

Conference JOURNAL OF IMMUNOLOGY · 2013 Cite

Mast cells impair the development of protective anti-tumor immunity.

Journal Article Cancer Immunol Immunother · December 2012 Mast cells have emerged as critical intermediaries in the regulation of peripheral tolerance. Their presence in many precancerous lesions and tumors is associated with a poor prognosis, suggesting mast cells may promote an immunosuppressive tumor microenvi ... Full text Link to item Cite

Editorial: A clear vision needs some balance.

Journal Article J Leukoc Biol · November 2012 Full text Link to item Cite

Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?

Journal Article Am J Physiol Lung Cell Mol Physiol · September 15, 2012 In the clinical setting, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene enhance the inflammatory response in the lung to Pseudomonas aeruginosa (P. aeruginosa) infection. However, studies on human airway epithelial cells i ... Full text Link to item Cite

Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma.

Journal Article J Cell Sci · September 15, 2012 Telomeres play crucial roles in the maintenance of genome integrity and control of cellular senescence. Most eukaryotic telomeres can be transcribed to generate a telomeric repeat-containing RNA (TERRA) that persists as a heterogeneous nuclear RNA and can ... Full text Link to item Cite

Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles.

Journal Article Oncoimmunology · September 1, 2012 Current ovarian cancer treatments based on surgery/chemotherapy show limited efficacy. Targeting immunosuppression is a requirement for the effectiveness of novel promising anti-tumor immunotherapies. Our latest work in preclinical models shows that nanopa ... Full text Link to item Cite

Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.

Journal Article Expert Rev Obstet Gynecol · September 1, 2012 After more than 30 years of iterations of surgical debulking plus chemotherapy, the need for complementary ovarian cancer treatments has become clear. In the ovarian cancer microenvironment, myeloid immunosuppressive leukocytes, lymphocytes, fibroblasts an ... Full text Link to item Cite

Mesothelin, a novel immunotherapy target for triple negative breast cancer.

Journal Article Breast Cancer Res Treat · June 2012 Mesothelin is a cell-surface glycoprotein present on mesothelial cells and elicits T cell responses in a variety of cancers including pancreatic, biliary and ovarian cancer. Breast cancer is not known to express mesothelin. We postulated that mesothelin ma ... Full text Link to item Cite

Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Journal Article Cancer Res · April 1, 2012 Modulating the activity of miRNAs provides opportunities for novel cancer interventions. However, low bioavailability and poor cellular uptake are major challenges for delivering miRNA mimetics specifically to tumor cells. Here, we took advantage of the sp ... Full text Link to item Cite

Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.

Journal Article J Exp Med · March 12, 2012 We characterized the initiation and evolution of the immune response against a new inducible p53-dependent model of aggressive ovarian carcinoma that recapitulates the leukocyte infiltrates and cytokine milieu of advanced human tumors. Unlike other models ... Full text Link to item Cite

Double agents in the war on cancer: leukocytes govern ovarian cancer progression.

Journal Article Oncotarget · March 2012 In conclusion, our work expands our understanding of tumor progression and provides further mechanistic rationale to develop novel interventions targeting immunosuppression. Future studies should unveil other unrecognized aspects of the contribution of the ... Full text Link to item Cite

Anti-tumor immunity: myeloid leukocytes control the immune landscape.

Journal Article Cell Immunol · 2012 The immune surveillance hypothesis proposed over 50 years ago that many precancerous lesions are eliminated without a histological trace due to immunological pressure. Since then, it has become apparent that both the tumor and the anti-cancer immune respon ... Full text Link to item Cite

Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm.

Chapter · 2012 The lack of targeted therapy for women with triple negative breast cancer demands a "think-outside-the-box" approach in search of novel treatment strategies. Although cancer drug development traditionally focused on targeting the tumor cell cycle, emphasis ... Full text Link to item Cite

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

Journal Article Oncotarget · September 2010 CD277, a member of the butyrophilin subfamily 3 (BTN3), shares significant sequence similarities and predicted common structural features with inhibitory B7-H4 and other members of the B7 superfamily. Here we report that CD277 is consistently expressed in ... Full text Link to item Cite

Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors.

Journal Article Clin Cancer Res · August 15, 2010 PURPOSE: High-throughput profiling experiments have linked altered expression of microRNAs (miRNA) to different types of cancer. Tumor tissues are a heterogeneous mixture of not only cancer cells, but also supportive and reactive tumor microenvironment ele ... Full text Link to item Cite

CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.

Journal Article J Immunol · May 15, 2010 T cell adoptive transfer strategies that have produced clinical remissions against specific tumors have so far produced disappointing results against ovarian cancer. Recent evidence suggests that adoptively transferred CD4(+) T cells can trigger endogenous ... Full text Link to item Cite

Abstract LB-360: Fluorescence-based co-registration with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors

Conference Cancer Research · April 15, 2010 AbstractMicroRNAs (miRNAs) are a class of short non-coding regulatory RNA genes, which have been implicated in the control of developmental, physiological and pathological processes. High-throughput profilin ... Full text Cite

Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration.

Journal Article J Exp Med · March 15, 2010 RNA splicing is an increasingly recognized regulator of immunity. Here, we demonstrate that after Mycobacterium tuberculosis infection (mRNA) il12rb1 is spliced by dendritic cells (DCs) to form an alternative (mRNA) il12rb1Deltatm that encodes the protein ... Full text Link to item Cite

Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.

Journal Article Cell Cycle · January 15, 2010 Current therapies for metastatic ovarian carcinoma are based on surgical debulking followed by chemotherapy. After more than three decades implementing treatments that selectively target the tumor cell, the 5-year survival rate for metastatic ovarian cance ... Full text Link to item Cite

Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.

Journal Article Clin Dev Immunol · 2010 Adoptive T cell transfer therapy, the ex vivo activation, expansion, and subsequent administration of tumor-reactive T cells, is already the most effective therapy against certain types of cancer. However, recent evidence in animal models and clinical tria ... Full text Link to item Cite

In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

Journal Article Cancer Res · September 15, 2009 Boosting therapeutically relevant immunity against lethal epithelial tumors may require targeting tumor-induced immunosuppression on an individualized basis. Here, we show that, in the ovarian carcinoma microenvironment, CD11c(+)MHC-II(+) dendritic cells s ... Full text Link to item Cite

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Journal Article J Clin Invest · August 2009 The success of clinically relevant immunotherapies requires reversing tumor-induced immunosuppression. Here we demonstrated that linear polyethylenimine-based (PEI-based) nanoparticles encapsulating siRNA were preferentially and avidly engulfed by regulato ... Full text Link to item Cite

CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.

Journal Article Cancer Res · August 1, 2009 Adoptive transfer of antitumor T cells is a promisingly effective therapy for various cancers, but its effect on endogenous antitumor immune mechanisms remains largely unknown. Here, we show that the administration of naive T cells de novo primed for only ... Full text Link to item Cite

Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer.

Journal Article J Transl Med · June 19, 2009 BACKGROUND: Murine studies suggest that myeloid cells such as vascular leukocytes (VLC) and Tie2+ monocytes play a critical role in tumor angiogenesis and vasculogenesis. Myeloid cells are a primary cause of resistance to anti-VEGF therapy. The elimination ... Full text Link to item Cite

Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs.

Journal Article Am J Reprod Immunol · January 2009 PROBLEM: The initiation of an immune response often involves the cooperation of various innate immune cells. In the human endometrium, uterine natural killer (uNK) cells and uterine macrophages are present in significant numbers and in close proximity, yet ... Full text Link to item Cite

Estradiol regulates MICA expression in human endometrial cells.

Journal Article Clin Immunol · November 2008 The human endometrium undergoes cyclical changes regulated by sex hormones. Evidence suggests that sex hormones regulate NK cell recruitment into the uterus in large numbers. NKG2D is an activating receptor expressed on human NK cells, gammadelta and CD8 T ... Full text Link to item Cite

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Journal Article Cancer Res · September 15, 2008 Dendritic cells (DC) and cytokines that expand myeloid progenitors are widely used to treat cancer. Here, we show that CD11c(+)DEC205(+) DCs coexpressing alpha-smooth muscle actin and VE-cadherin home to perivascular areas in the ovarian cancer microenviro ... Full text Link to item Cite

PILAR is a novel modulator of human T-cell expansion.

Journal Article Blood · August 15, 2008 Robust T-cell responses without autoimmunity are only possible through a fine balance between activating and inhibitory signals. We have identified a novel modulator of T-cell expansion named proliferation-induced lymphocyte-associated receptor (PILAR). Su ... Full text Link to item Cite

Role of vascular leukocytes in ovarian cancer neovascularization.

Chapter · 2008 Vascular leukocytes are a unique population of CD45+ VE-cadherin+ cells with diverse functions. VLCs are capable of antigen presentation, as well as formation of endothelial-like structures in vitro and in vivo. VLCs are largely present among CD45+ cells i ... Full text Link to item Cite

Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.

Journal Article Cancer Res · May 15, 2007 Despite advancements in the treatment of ovarian cancer, this disease continues to be a leading cause of cancer death in women. Adoptive transfer of tumor-reactive T cells is a promising antitumor therapy for many cancers. We designed a chimeric receptor l ... Full text Link to item Cite

Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.

Journal Article Cancer Res · May 15, 2007 Immunosuppressive leukocytes are emerging as a critical factor in facilitating tumor progression. These leukocytes are converted by the tumor microenvironment to become tolerogenic, facilitate metastasis, and to aid in neovascularization. The predominant v ... Full text Link to item Cite

Immune biomarkers in ovarian cancer

Chapter · January 1, 2007 Emerging evidence over the past decade has revealed the significance of tumor-host interactions and of the tumor microenvironment in tumor growth and progression. Among these mechanisms, a bulk of experimental evidence in animal tumor models has clearly es ... Cite

Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity.

Journal Article Cancer Biol Ther · July 2006 We tested whether tumor cells were killed by replication-incompetent recombinant herpes simplex virus (HSV) d120 lacking immediate early gene ICP4 and whether HSVd120-killed tumor cells could be used directly for tumor vaccination. Vaccine efficacy was tes ... Full text Link to item Cite

Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment.

Journal Article Cancer Biol Ther · June 2006 Expression profiling using microarrays has become an essential tool for interrogating tumor biology. However, profiling of whole tumor RNA reflects both tumor and host cells, making it difficult to dissect molecular events within specific cellular compartm ... Full text Link to item Cite

Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines.

Journal Article Cancer Gene Ther · February 2006 The use of dendritic cells (DCs) loaded with apoptotic tumor cells is an attractive approach to tumor vaccination in the absence of well-characterized tumor antigens. Apoptotic tumor cells are a convenient source of polyvalent tumor antigen, but may induce ... Full text Link to item Cite

Contribution of immune cell-derived growth factors to the pathogenesis of endometrial carcinoma.

Conference JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION · 2006 Cite

HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.

Journal Article Mol Ther · November 2005 Cooperation between oncolytic herpes simplex virus (HSV) and host effector immune mechanisms has been previously described. In the present study, we investigated the mechanism underlying such cooperation in a murine syngeneic model of ovarian carcinoma. Th ... Full text Link to item Cite

Immunotherapy for gynaecological malignancies.

Journal Article Expert Opin Biol Ther · September 2005 Gynaecological malignancies, excluding breast cancer, cause approximately 25,000 deaths yearly among women in the US. Therefore, novel approaches for the prevention or treatment of these diseases are urgently required. In the case of cervical cancer, human ... Full text Link to item Cite

Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.

Journal Article Hum Gene Ther · June 2005 In the present study, we investigated the ability of replication-restricted herpes simplex virus (HSV) 1716 lacking ICP34.5 to infect endothelium and disrupt tumor vasculature. HSV-1716 efficiently infected and killed mouse endothelial cell lines H5V and M ... Full text Link to item Cite

The role of dendritic cell precursors in tumour vasculogenesis.

Journal Article Br J Cancer · April 11, 2005 In this review, we discuss the recent identification in vivo of a population of CD11c+ cells exhibiting simultaneous expression of both endothelial and dendritic cell markers, termed vascular leukocytes (VLCs). VLCs are highly represented in human ovarian ... Full text Link to item Cite

Vascular leukocytes contribute to tumor vascularization.

Journal Article Blood · January 15, 2005 There is no proof that hematopoietic cells contribute significantly to vasculogenesis in postnatal life. Here we report a novel leukocyte subset within ovarian carcinoma that coexpresses endothelial and dendritic cell markers. Fluorescence-activated cell s ... Full text Link to item Cite

Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A.

Journal Article Nat Med · September 2004 The involvement of immune mechanisms in tumor angiogenesis is unclear. Here we describe a new mechanism of tumor vasculogenesis mediated by dendritic cell (DC) precursors through the cooperation of beta-defensins and vascular endothelial growth factor-A (V ... Full text Link to item Cite

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Journal Article Nat Med · September 2004 Regulatory T (T(reg)) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells. Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-associated antigen-reactive lymphocytes mediated by T(reg) cells; ... Full text Link to item Cite

Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells.

Journal Article Cancer Res · March 15, 2004 The role of the NKG2D immunoreceptor and its ligands in antitumor immune response is incompletely understood. Here, we report that effector immune cells infiltrating ovarian carcinoma are mostly CD8+ lymphocytes lacking CD28 but expressing the NKG2D costim ... Full text Link to item Cite

Antioxidant nutrients protect against cyclosporine A nephrotoxicity.

Journal Article Toxicology · July 15, 2003 The immunosuppressive drug cyclosporine A (CsA) has been successfully used in several diseases with immunological basis and in transplant patients. Nephrotoxicity is the main secondary effect of CsA treatment. Although the mechanisms of nephrotoxitity are ... Full text Link to item Cite

T cells in ovarian cancer.

Journal Article N Engl J Med · May 1, 2003 Full text Link to item Cite

Distribution of new human beta-defensin genes clustered on chromosome 20 in functionally different segments of epididymis.

Journal Article Genomics · February 2003 Human beta-defensins are a family of cationic peptides that share a pattern of six conserved cysteine residues. We describe the cloning and characterization of the cDNAs of five novel beta-defensin genes (DEFB25-DEFB29) clustered on chromosome 20p13, which ... Full text Link to item Cite

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Journal Article N Engl J Med · January 16, 2003 BACKGROUND: Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical outcome has not been established. METHODS: We performed immunohistochemical analysis of 186 frozen specimens from advanced-stage ov ... Full text Link to item Cite

Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells.

Journal Article Cancer Biol Ther · 2003 NKG2D serves as one of the most potent activating receptors for effector lymphocytes. in peripheral tissues. Here we report the characterization of Letal, the first human trans-membrane NKG2D ligand lacking an immunoglobulin-like alpha-3 ectodomain. Letal ... Full text Link to item Cite

Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver.

Journal Article Protein Sci · January 2003 The human genome contains numerous genes whose protein products are unknown in terms of structure, interaction partner, expression, and function. To unravel the function of these orphan genes, it is of particular value to isolate native forms of protein an ... Full text Link to item Cite

Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma.

Journal Article Clin Cancer Res · January 2003 The first tissue-specific angiogenic molecule, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), was identified recently in human ovary, raising hopes of developing tumor type-specific angiogenesis inhibitors. In the present study, we a ... Link to item Cite

T cells in ovarian cancer - Reply

Journal Article NEW ENGLAND JOURNAL OF MEDICINE · 2003 Cite

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Journal Article Am J Pathol · December 2002 Vascular endothelial growth factor (VEGF) performs multifaceted functions in the tumor microenvironment promoting angiogenesis, suppressing anti-tumor immune response, and possibly exerting autocrine functions on tumor cells. However, appropriate syngeneic ... Full text Link to item Cite

Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells.

Journal Article Biochem Biophys Res Commun · April 12, 2002 Vascular endothelial growth factor (VEGF) has been implicated as a potent regulator of angiogenesis in tumors, and its protein exists as at least five isoforms with distinct biologic activities and clinical significance. Tumors under metabolic stress condi ... Full text Link to item Cite

Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity.

Journal Article Protein Sci · December 2001 Defensins are cationic and cysteine-rich peptides that play a crucial role in the host defense against microorganisms of many organisms by their capability to permeabilize bacterial membranes. The low sequence similarity among the members of the large mamm ... Full text Link to item Cite

Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction.

Journal Article Cell Tissue Res · November 2001 Previous studies have shown the implication of beta-defensins in host defense of the human body. The human beta-defensins 1 and 2 (hBD-1, hBD-2) have been isolated by biochemical methods. Here we report the identification of a third human beta-defensin, ca ... Full text Link to item Cite

Real-time quantitative PCR of telomerase mRNA is useful for the differentiation of benign and malignant pancreatic disorders.

Journal Article Pancreas · May 2001 The presence of telomerase activity has been proposed as a specific and sensitive marker for malignant tissue, and positivity rates of up to 95% have been reported in pancreatic cancer. In the present study telomerase activity analysis was reevaluated in 2 ... Full text Link to item Cite

NK-1 receptor gene expression is related to pain in chronic pancreatitis.

Journal Article Pain · April 2001 Recent theories of pathogenesis of pain in chronic pancreatitis (CP) are neuroimmune interactions of intrapancreatic nerves and inflammatory cells and increase in levels of pain neurotransmitters such as substance P (SP). This study analyzed the expression ... Full text Link to item Cite

Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5.

Journal Article Surgery · November 2000 BACKGROUND: The immunologic mechanisms involved in the development of chronic pancreatitis (CP) are poorly understood. Chronically inflamed tissues contain increased numbers of mononuclear cells expressing the CC chemokine receptor 5 (CCR5), which is also ... Full text Link to item Cite

Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers.

Journal Article Int J Cancer · October 1, 2000 Syndecan-1 belongs to the syndecan family of cell surface transmembrane heparan-sulfate proteoglycans, which participate in cell proliferation, cell migration and cell-matrix interactions. Decreased expression of syndecan-1 has been observed in some gastro ... Full text Link to item Cite

Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity.

Journal Article Transplantation · November 27, 1998 BACKGROUND: We report an investigation of the effects of cyclosporine (CsA) on kidney function, the glomerular synthesis of reactive oxygen species, the peroxidation of lipids, and the levels of thromboxane B2 (TXB2). The effect of the simultaneous adminis ... Full text Link to item Cite

Diagnostic value of three tumor markers determined in pleural effusions.

Journal Article Eur J Clin Chem Clin Biochem · February 1996 In order to discriminate between malignant and benign effusions, the values of tissue polypeptide specific antigen,carcinoembryonic antigen and squamous cell carcinoma associated antigen were measured in the pleural fluid of 30 patients with neoplasm, 10 w ... Link to item Cite

Evaluation of zone electrophoresis of serum proteins performed on the Helena Laboratories rapid electrophoresis analyser.

Journal Article Scand J Clin Lab Invest · December 1995 Zone electrophoresis of serum proteins is still widely performed as a routine procedure in clinical laboratories. It is used in the diagnosis and management of many disorders, e.g. monoclonal gammopathies, cirrhosis, nephrotic syndrome, acute-phase reactio ... Full text Link to item Cite